CD3+ and CD8+ T cell-based immune cell score as a prognostic factor in clear-cell renal cell carcinoma

Authors

  • Jonne Åkerla Department of Urology, Tampere University Hospital, Tampere, Finland https://orcid.org/0000-0002-0861-6569
  • Olli Helminen Cancer and Translational Medicine Research Unit, Medical Research Centre, University of Oulu and Oulu University Hospital, Oulu, Finland; Department of Gastrointestinal Surgery, Oulu University Hospital, Oulu, Finland
  • Juha P. Väyrynen Cancer and Translational Medicine Research Unit, Medical Research Centre, University of Oulu and Oulu University Hospital, Oulu, Finland
  • Anne Parkkinen Department of Surgery, Hospital Nova of Central Finland, Jyväskylä, Finland
  • Hilma Järvenpää Department of Surgery, Hospital Nova of Central Finland, Jyväskylä, Finland
  • Jan Böhm Department of Pathology, Hospital Nova of Central Finland, Jyväskylä, Finland
  • Maarit Ahtiainen Department of Pathology, Hospital Nova of Central Finland, Jyväskylä, Finland
  • Heikki Seikkula Department of Surgery, Hospital Nova of Central Finland, Jyväskylä, Finland

DOI:

https://doi.org/10.2340/1651-226X.2024.19690

Keywords:

Carcinoma, renal cell, immunohistochemistry, immune cell score, CD3, CD8, Prognosis

Abstract

Background and purpose: Immunoscore® is a prognostic parameter based on densities of lymphocyte populations in the tumor center and invasive margin. Immunoscore® is validated in colorectal cancer as a high Immunoscore® is associated with longer survival. Previous studies have suggested that Immunoscore® may also predict oncological outcomes in clear-cell renal cell carcinoma (ccRCC). This study aims to assess the prognostic role of immune cell score in ccRCC.

Material and methods: All patients with ccRCC undergoing surgery between 2007 and 2020 in Central Finland Central Hospital were retrospectively identified. CD3+ and CD8+ cell densities were calculated from tissue samples to determine the immune cell score using Immunoscore® principles. Receiver-operating characteristic analysis, Kaplan–Meier survival curve, and Cox regression were used to evaluate the association between immune cell score and survival.

Results: A total of 203 patients (mean age 66.5 years) were identified. The median follow-up time was 6.2 years. Based on the immune cell score, the patients were divided into three groups: low, intermediate, and high. In Cox regression analysis, adjusted with age, sex, and Charlson Comorbidity Index, no significant differences in disease-specific mortality were observed among the three groups. The hazard ratios (HRs) for disease-specific mortality were 0.93 (95% confidence interval [CI] 0.48–1.79) and 1.12 (0.52–2.37) for intermediate- and high-immune cell score groups when compared to low-immune cell score group, respectively.

Interpretation: This study found no association between immune cell score and survival. These results indicate that immune cell score may not serve as a prognostic tool in ccRCC.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/CAAC.21660 DOI: https://doi.org/10.3322/caac.21660

Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79. https://doi.org/10.14740/WJON1279 DOI: https://doi.org/10.14740/wjon1279

Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2015;67(1):85–97. https://doi.org/10.1016/j.eururo.2014.04.029 DOI: https://doi.org/10.1016/j.eururo.2014.04.029

Brierley J, Gospodarowicz MD, Wittekind CT. TNM classification of malignant tumors international union against cancer [Internet]. 8th ed. Oxford: Wiley; 2017 , p. 57–62. [cited 28-12-2022]. Available from: https://www.wiley.com/en-nl/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263562

Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24. https://doi.org/10.1016/j.eururo.2015.01.005 DOI: https://doi.org/10.1016/j.eururo.2015.01.005

Cancer SEER. Kidney and renal pelvis cancer – Cancer stat facts [Internet]. NIH, National Cancer Institute; 2018. [cited 28-12-2022]. Availa-ble from: https://seer.cancer.gov/statfacts/html/kidrp.html

Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36(12):1943–52. https://doi.org/10.1007/S00345-018-2309-4 DOI: https://doi.org/10.1007/s00345-018-2309-4

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99. https://doi.org/10.1016/j.cell.2010.01.025 DOI: https://doi.org/10.1016/j.cell.2010.01.025

Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to dis-tant metastasis. Sci Transl Med. 2016;8(327):327ra26. https://doi.org/10.1126/scitranslmed.aad6352 DOI: https://doi.org/10.1126/scitranslmed.aad6352

Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28(8):373–82. https://doi.org/10.1093/INTIMM/DXW021 DOI: https://doi.org/10.1093/intimm/dxw021

Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognos-tic and accuracy study. Lancet. 2018;391(10135):2128–39. https://doi.org/10.1016/S0140-6736(18)30789-X DOI: https://doi.org/10.1016/S0140-6736(18)30789-X

Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80. https://doi.org/10.1038/s41568-020-0285-7 DOI: https://doi.org/10.1038/s41568-020-0285-7

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Ann Rev Immunol. 2011;29(1):235–71. https://doi.org/10.1146/annurev-immunol-031210-101324 DOI: https://doi.org/10.1146/annurev-immunol-031210-101324

Selvi I, Demirci U, Bozdogan N, Basar H. The prognostic effect of Immunoscore in patients with clear cell renal cell carcinoma: preliminary results. Int Urol Nephrol. 2020;52(1):21–34. https://doi.org/10.1007/S11255-019-02285-0 DOI: https://doi.org/10.1007/s11255-019-02285-0

Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https://doi.org/10.1038/S41598-017-17204-5 DOI: https://doi.org/10.1038/s41598-017-17204-5

Selvi I, Demirci U, Bozdogan N, Basar H. Does Immunoscore have a significant effect on survival for non-clear cell renal cell carcinoma as well as clear cell renal cell carcinoma? Int Urol Nephrol. 2021;53(6):1135–38. https://doi.org/10.1007/S11255-020-02766-7/METRICS DOI: https://doi.org/10.1007/s11255-020-02766-7

Guo C, Zhao H, Wang Y, et al. Prognostic value of the neo-Immunoscore in renal cell carcinoma. Front Oncol. 2019;9:439. https://doi.org/10.3389/FONC.2019.00439 DOI: https://doi.org/10.3389/fonc.2019.00439

Nakano O, Naito Y, Nagura H, et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132–6.

Giraldo NA, Becht E, Pagès F, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031–40. https://doi.org/10.1158/1078-0432.CCR-14-2926 DOI: https://doi.org/10.1158/1078-0432.CCR-14-2926

Zhang S, Zhang E, Long J, et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 2019;110(5):1564–72. https://doi.org/10.1111/CAS.13996 DOI: https://doi.org/10.1111/cas.13996

Junttila A, Väyrynen JP, Ahtiainen M, et al. Immune cell score, PD-L1 expression and prognosis in esophageal cancer. Acta Oncol. 2021;60(4):544–8. https://doi.org/10.1080/0284186X.2020.1868571 DOI: https://doi.org/10.1080/0284186X.2020.1868571

Junttila A, Helminen O, Väyrynen JP, et al. Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 mac-rophages predicts survival in gastric cancer. Br J Cancer. 2020;123(11):1625–32. https://doi.org/10.1038/S41416-020-01053-7 DOI: https://doi.org/10.1038/s41416-020-01053-7

Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019;9(10):1349–57. https://doi.org/10.1158/2159-8290.CD-19-0499 DOI: https://doi.org/10.1158/2159-8290.CD-19-0499

Kim MC, Jin Z, Kolb R, et al. Updates on immunotherapy and immune landscape in renal clear cell carcinoma. Cancers (Basel). 2021;13(22):5856. https://doi.org/10.3390/CANCERS13225856 DOI: https://doi.org/10.3390/cancers13225856

Downloads

Additional Files

Published

2024-03-28

How to Cite

Åkerla, J., Helminen, O., Väyrynen, J. P., Parkkinen, A., Järvenpää, H., Böhm, J., … Seikkula, H. (2024). CD3+ and CD8+ T cell-based immune cell score as a prognostic factor in clear-cell renal cell carcinoma. Acta Oncologica, 63(1), 105–110. https://doi.org/10.2340/1651-226X.2024.19690

Issue

Vol. 63 (2024): Acta Oncologica

Section

Short report

Categories

License

Copyright (c) 2024 Jonne Åkerla, Olli Helminen, Juha P. Väyrynen, Anne Parkkinen, Hilma Järvenpää, Jan Böhm, Maarit Ahtiainen, Heikki Seikkula

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.